尤瑞克林对部分糖代谢异常的缺血性脑卒中患者nhiss评分及认知功能影响的研究

《尤瑞克林对部分糖代谢异常的缺血性脑卒中患者nhiss评分及认知功能影响的研究》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码10089学号或申请号20153220中国图书分类号R743HebeiMedicalUniversity硕士学位论文专业学位尤瑞克林对部分糖代谢异常的缺血性脑卒中患者NHISS评分及认知功能影响的研究研究生：陈蕾导师：王晓鹏教授专业：神经内科二级学院：河北医科大学第二医院2018年3月目录中文摘要········································································································1英文摘要··············

2、·····························································································2英文缩写············································································································4研究论文尤瑞克林对部分糖代谢异常的缺血性脑卒中患者NIHSS评分及认知功能影响的研究前言···························

3、············································································5资料与方法······························································································6结果···································································································

4、·······8附表···········································································································9讨论···································································································12结论·······················································

5、··················································15参考文献································································································15综述血管性认知障碍研究进展·····································································18致谢······································

6、············································································32个人简历·········································································································33中文摘要尤瑞克林对部分糖代谢异常的缺血性脑卒中患者NHISS评分及认知功能影响的研究摘要目的：本文旨在评估尤瑞克林对AIS合并糖尿病（DM）及空腹血糖调节受损(IFG)患者NIH

7、SS评分和认知功能的影响，并初步探讨可能的作用机制。方法：收治合并DM或IFG的急性脑梗死患者162例，分为试验组、对照组，试验组在对照组基础上加用尤瑞克林治疗。于入院当天、治疗后10d、30d、90d评估两组患者NIHSS评分，于治疗后10d、30d、90d评估患者MoCA评分。结果：1.治疗后10d、30d、90d两组患者NHISS评分相比基线（入院）均有所下降。治疗后10d与基线相比，试验组NIHSS评分下降更明显，两组间有统计学差异（P=0.0001，P<0.05）；30d试验组下降较对照组明显，但无统计学差异（P=0.6542，P>0.05

8、）；90d相比基线：两组均下降，无统计学差异（P=0.4227，P>0.05）；2.治疗后30d、90d相比